If you have non-cystic fibrosis bronchiectasis, you’re likely an expert on the “lung side” of the disease — the stubborn mucus, the nagging cough, and the constant threat of a flare-up. But by causing ...

When you’re living with bronchiectasis, your primary goal in managing the condition is to reduce “exacerbations” — episodes in which you’re coughing, breathless, and making more phlegm — and to ...

DPP‑1 inhibitors and long‑term macrolides appeared to effectively reduce the frequency of exacerbations in patients with non-cystic fibrosis bronchiectasis compared with placebo, with macrolides ...

This activity is provided by National Jewish Health. Bronchiectasis is a complex and increasingly prevalent condition often overlooked in clinical practice, with frequent overlap with other ...

Miami (October 23, 2025) – The Bronchiectasis and NTM Association announced today that two abstracts using Bronchiectasis and NTM Research Registry data were presented at CHEST 2025, held October ...

Miami (October 2, 2025) – The Bronchiectasis and NTM Association announced today that two abstracts using Bronchiectasis and NTM Research Registry data were presented at the European Respiratory ...

Queen's University Belfast-led research reports on a multicenter trial finding no significant reduction in pulmonary exacerbations with hypertonic saline or carbocisteine over 52 weeks among adults ...

Bronchiectasis guidelines are inconsistent with regard to the effectiveness of mucoactive agents, and their use varies geographically. Large trials are needed to assess safety and effectiveness. For ...

Add Yahoo as a preferred source to see more of our stories on Google. Sep. 24—(StatePoint) Getting the correct treatment for bronchiectasis, a chronic lung condition affecting 350,000 to 500,000 ...

Prior exacerbations and greater symptom severity independently predicted future exacerbations in patients with bronchiectasis. Long-term macrolide proved beneficial not only for patients with frequent ...